KSP Inc.
Japanese business incubator operating as the core entity of Kanagawa Science Park (KSP), supporting R&D-oriented ventures.
Last updated September 10, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
KSP Inc. (株式会社ケイエスピー) is a Japanese company that operates as the core business entity of Kanagawa Science Park (KSP). It was founded in 1986 as Japan's first third-sector company, with investment from Kanagawa Prefecture, Kawasaki City, the national government, and private companies. It provides incubation services for R&D-oriented ventures, including offices and labs at three science park locations in Kawasaki City (KSP, KSP-Think, KSP Biotech Lab), investment funds, business matching, and a business innovation school. It has been involved in the creation, growth, and IPO of over 300 venture companies.
History
KSP Inc. was founded in 1986 as the core business entity of Kanagawa Science Park (KSP), described as the second science park in Asia. It was established as Japan's first third-sector company, with investment from Kanagawa Prefecture, Kawasaki City, the national government, and private companies. The company has operated as a pioneer of business incubation supporting the founding and growth of R&D-oriented ventures. It began investment activities before laws concerning funds were enacted, and a cumulative total of 19 portfolio companies have gone public. Its Business Innovation School has produced over 750 graduates, and its business matching activities, held since 2002, have involved over 2,500 individual meetings between SMEs/ventures and large companies. The company has been involved in the creation, growth, and IPO of over 300 venture companies.
Products and positioning
A pioneer of business incubation in Japan, supporting R&D-oriented ventures from startup through growth.
Sources6 sources
- 1株式会社ケイエスピー | 明日の新事業を協創するケイエスピーksp.co.jp
- 2株式会社ケイエスピーのあゆみ | 明日の新事業を協創するケイエスピーksp.co.jp
- 3会社情報 | 明日の新事業を協創するケイエスピーksp.co.jp
- 4ビジョン | 明日の新事業を協創するケイエスピーksp.co.jp
- 5KSP Inc (Japan)wikidata.org
- 6Metcela Secures $12.7 Million Series B Financing to Initiate Phase I Clinical Trial in Chronic Heart Failure for MTC001 Cell Therapyprweb.com
Cite this profile: Cite the canonical profile. /brand-wiki/ksp · Editorial policy · How profiles are compiled